United States · Markets & Finance · MarketWatch

Alector Enters Licensing Agreement With Genentech for Parkinson's Therapy

Published by MarketWatch · United States 10 h ago

Alector entered into an exclusive global licensing agreement with Genetech, which will receive worldwide rights to develop and commercialize Alector's AL050 program.

Read the full article on MarketWatch Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketwatch.com)

Also worth reading

OilPrice.com

Rubio Opens 4-Day NATO Tour in Iceland to Discuss Arctic Security

TechCrunch

The final Disrupt Stage lineup: Three days of conversations you won’t hear anywhere outside of TechCrunch Disrupt 2026

Seeking Alpha

Alector Enters Licensing Agreement With Genentech for Parkinson's Therapy

Share

Also worth reading

Rubio Opens 4-Day NATO Tour in Iceland to Discuss Arctic Security

The final Disrupt Stage lineup: Three days of conversations you won’t hear anywhere outside of TechCrunch Disrupt 2026

Half of bond ETFs now show negative one-year returns

My partner and I always thought we agreed on money. Then, we moved in together.

Metaplanet reveals net income strategy to fuel Bitcoin accumulation

Stripe to expand stablecoin cards to over 100 countries by the end of the year